Abstract
A current debate in the HIV-1 vaccine field concerns the ability of an immunodeficiency virus to elicit a protective response. One argument is that HIV-1 superinfections are frequent in healthy individuals, because virus evades conventional immune surveillance, a serious obstacle to vaccine design. The opposing argument is that protection from superinfection is significant, reflecting a robust immune response that might be harnessed by vaccination to prevent disease. In an experiment designed to address the debate, two macaques received an I.V. inoculation with SHIV KU-1-d (a derivative of SHIV KU-1) and were rested for > 10 months. Infection elicited diverse neutralizing antibody activities in both animals. Animals were then exposed to SHIV 89.6P (I.V.), a virus carrying a heterologous envelope protein relative to the vaccine strain. Infection was monitored by viral load and CD4+ T-cell measurements. All control animals were infected and most succumbed to disease. In contrast, protection from superinfection was statistically significant in test monkeys; one animal showed no evidence of superinfection at any time point and the second showed evidence of virus at only one time point over a 6-month observation period. Neither animal showed signs of disease. Perhaps this protective state may serve as a ‘gold-standard’ for HIV-1 vaccine development, as a similar degree of protection against immunodeficiency virus infections in humans would be much desired.
Keywords: Rhesus macaques, Protective immunity, SHIV, Neutralization, Vaccine
Current HIV Research
Title: SHIV Infection Protects Against Heterologous Pathogenic SHIV Challenge in Macaques: A Gold-Standard for HIV-1 Vaccine Development?
Volume: 7 Issue: 5
Author(s): Robert Sealy, Xiaoyan Zhan, Timothy D. Lockey, Louis Martin, James Blanchard, Vicki Traina-Dorge and Julia L. Hurwitz
Affiliation:
Keywords: Rhesus macaques, Protective immunity, SHIV, Neutralization, Vaccine
Abstract: A current debate in the HIV-1 vaccine field concerns the ability of an immunodeficiency virus to elicit a protective response. One argument is that HIV-1 superinfections are frequent in healthy individuals, because virus evades conventional immune surveillance, a serious obstacle to vaccine design. The opposing argument is that protection from superinfection is significant, reflecting a robust immune response that might be harnessed by vaccination to prevent disease. In an experiment designed to address the debate, two macaques received an I.V. inoculation with SHIV KU-1-d (a derivative of SHIV KU-1) and were rested for > 10 months. Infection elicited diverse neutralizing antibody activities in both animals. Animals were then exposed to SHIV 89.6P (I.V.), a virus carrying a heterologous envelope protein relative to the vaccine strain. Infection was monitored by viral load and CD4+ T-cell measurements. All control animals were infected and most succumbed to disease. In contrast, protection from superinfection was statistically significant in test monkeys; one animal showed no evidence of superinfection at any time point and the second showed evidence of virus at only one time point over a 6-month observation period. Neither animal showed signs of disease. Perhaps this protective state may serve as a ‘gold-standard’ for HIV-1 vaccine development, as a similar degree of protection against immunodeficiency virus infections in humans would be much desired.
Export Options
About this article
Cite this article as:
Sealy Robert, Zhan Xiaoyan, Lockey D. Timothy, Martin Louis, Blanchard James, Traina-Dorge Vicki and Hurwitz L. Julia, SHIV Infection Protects Against Heterologous Pathogenic SHIV Challenge in Macaques: A Gold-Standard for HIV-1 Vaccine Development?, Current HIV Research 2009; 7 (5) . https://dx.doi.org/10.2174/157016209789346255
DOI https://dx.doi.org/10.2174/157016209789346255 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Opening Pandora’s (Tool) Box: Health Care Construction and Associated Risk for Nosocomial Infection.
Infectious Disorders - Drug Targets Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Immunity to Tumour Antigens
Current Pharmaceutical Design Evaluation on Auto-segmentation of the Clinical Target Volume (CTV) for Graves' Ophthalmopathy (GO) with a Fully Convolutional Network (FCN) on CT Images
Current Medical Imaging Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry An Uncommon Case of Symptomatic Multiple Meningiomas with Bilateral Compressive Optic Neuropathy Rapidly Induced under Cyprotero ne Acetate Treatment
Current Drug Safety Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Controversies in the Use of Nutritional Supplements in Ophthalmology
Current Pharmaceutical Design Predicting Drugs and Proteins in Parasite Infections with Topological Indices of Complex Networks: Theoretical Backgrounds, Applications and Legal Issues
Current Pharmaceutical Design Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy GABAA Receptor Channel Pharmacology
Current Pharmaceutical Design Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition
Anti-Cancer Agents in Medicinal Chemistry Interleukin-2 Immunotherapy and AIDS-Related Cytomegalovirus Retinitis
Current HIV Research General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination
Current Gene Therapy Synthesis, Biological Evaluation, Molecular Docking Study and Acute Oral Toxicity Study of Coupled Imidazole-Pyrimidine Derivatives
Letters in Drug Design & Discovery Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets